Cyteir Therapeutics scores $40.2 mln Series B
Lexington, Massachusetts-based Cyteir Therapeutics, a developer of next-generation synthetic lethal therapies for cancer, has secured $40.2 million in Series B funding. Novo Holdings led the round with participation from Venrock, DROIA Oncology Ventures, Osage University Partners, Lightstone Ventures and Celgene Corporation. As part of this closing, Dr. Karen Hong of Novo Ventures will join the Cyteir board.
15 October 2019•4 mins read
